Table 2.
Most common treatment-emergent all-grade and grade 3 to 4 AEs
| AE (MedDRA preferred term), n (%) | ven-idasa, n = 55 |
|
|---|---|---|
| All-grade AE∗ | Grade 3 to 4 AE† | |
| Diarrhea | 48 (87.3) | 3 (5.5) |
| Nausea | 41 (74.5) | 1 (1.8) |
| Vomiting | 29 (52.7) | 0 (0.0) |
| Hypokalemia | 28 (50.9) | 10 (18.2) |
| Febrile neutropenia | 25 (45.5) | 25 (45.5) |
| Decreased appetite | 18 (32.7) | 5 (9.1) |
| Hypomagnesemia | 17 (30.9) | 1 (1.8) |
| Neutropenia | 17 (30.9) | 17 (30.9) |
| Thrombocytopenia | 17 (30.9) | 16 (29.1) |
| Anemia | 16 (29.1) | 12 (21.8) |
| Asthenia | 14 (25.5) | 4 (7.3) |
| Fatigue | 14 (25.5) | 5 (9.1) |
| Constipation | 13 (23.6) | 0 (0.0) |
| Edema, peripheral | 12 (21.8) | 0 (0.0) |
| Pneumonia | 12 (21.8) | 10 (18.2) |
AEs were reported by the treating physician, categorized according to the Medical Dictionary for Regulatory Activities version 23.1, and graded per the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
MedDRA, Medical Dictionary for Regulatory Activities.
∗
Any grade AEs occurring in ≥25% of patients.
†
Grade 3 to 4 AEs occurring in ≥15% of patients.